Uveitis and Ocular Immunology Department, Narayana Nethralaya , Bangalore, India.
Vitreo Retina Department, Narayana Nethralaya , Bangalore, India.
Ocul Immunol Inflamm. 2020 May 18;28(4):667-675. doi: 10.1080/09273948.2019.1611878. Epub 2019 Aug 12.
To study morphology and treatment outcomes in serpiginous-like choroiditis (SLC).
A retrospective chart review of SLC cases with ≥1-year follow-up. SLC lesions with elongated borders, thin body named dendritic (D-SLC), large lesions still with elongated borders named advanced dendritic (AD-SLC), and lesions with rounded borders, thick body called placoid (P-SLC). History, investigations, treatment response, and relapses were studied.
Thirty-three eyes [D-SLC ( = 14), AD-SLC ( = 13), P-SLC ( = 6)] of 24 patients were studied. Resolution on Fundus autofluorescence achieved at 8.6 months (Range: 4-12 months). 0/16 eyes treated with anti-tubercular therapy (ATT) and 4/11 eyes treated without ATT had at least one recurrence in (D-SLC + AD-SLC) group ( = .019). Mean best corrected visual acuity at final follow-up was 20/20, 20/25, and 20/60 in D-SLC, AD-SLC, and in P-SLC, respectively.
P-SLC has poor visual prognosis compared to AD-SLC and D-SLC. ATT may prevent recurrences in D-SLC and AD-SLC.
研究匐行性脉络膜炎（SLC）的形态学和治疗结果。
对至少有 1 年随访的 SLC 病例进行回顾性图表审查。具有拉长边界、薄体的 SLC 病变称为树突状（D-SLC），较大的病变仍具有拉长边界称为高级树突状（AD-SLC），而具有圆形边界、厚体的病变称为盘状（P-SLC）。研究了病史、检查、治疗反应和复发情况。
研究了 24 名患者的 33 只眼[D-SLC（=14），AD-SLC（=13），P-SLC（=6）]。眼底自发荧光的分辨率在 8.6 个月（范围：4-12 个月）时达到。16 只眼接受抗结核治疗（ATT）中有 0 只，11 只眼未接受 ATT 中有 4 只（=0.019）至少有一次复发。最终随访时最佳矫正视力的平均值分别为 D-SLC 为 20/20、AD-SLC 为 20/25 和 P-SLC 为 20/60。
与 AD-SLC 和 D-SLC 相比，P-SLC 的视力预后较差。ATT 可能预防 D-SLC 和 AD-SLC 的复发。
